Ricevi le ultime notizie sulle azioni INmune Bio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di INMB

Ultime notizie per

INmune Bio

INmune Bio Inc

Aligos Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Equillium

FibroGen

Generation Bio

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

RenovoRx

Serina Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

INmune Bio (INMB) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Comments

INmune Bio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO